共同战“疫”：美国化学文摘社(CAS)联合研究人员和数据科学家加速COVID-19疗法研究

In This Together: CAS Joining Forces with Researchers and Data Scientists to Accelerate COVID-19 Treatments

曼努埃尔•古兹曼

Manuel Guzman

美国化学文摘社 总裁 (President, CAS)

截至到2020年4月9日，已确认的COVID-19病例超过140万例，而且可能还有更多未经测试的病例。全世界研究人员竞相寻找解决这一艰巨挑战的方案，包括探索利用已经批准的药物作为治疗药物、开发预防长期传播的疫苗，以及除药物发现之外的许多其他努力。为了保证一线医疗专业人员的安全，制造商正在重新构想生产过程，以制造关键用品，如洗手液和口罩，优化测试方法以更快、更准确地检测、开发抗新型病毒口罩的材料，和设计用于消毒医疗设备的新系统。

美国化学文摘社(CAS)的科学家和技术专家也在全力以赴地迎接这一挑战。作为全球科学界的一员，我们有机会、也有义务尽我们所能来应对这一严重影响如此众多生命的全球流行病。作为美国化学会(ACS)的分支机构，我们的使命是利用我们所有的资源、专业知识和能力来支持这场战斗。作为科学信息解决方案的专家，我们为加速COVID-19的研究和分析提供资源和洞察力，并积极与全球的研究和技术组织进行合作，以加速他们的工作。我们每天都在问自己，我们还能做些什么?

一种新常态，

不变的是质量和承诺

COVID-19危机给全球每个人都带来了独特的挑战，包括科研人员、专利局和期刊出版商。在美国化学文摘社，我们的首要任务仍然是确保客户的成功和我们运营的连续性，以及在这个充满挑战的时期我们员工的安全和幸福。

尽管处于这些特殊情况当中，CAS依然致力于保持我们所有客户都信赖的内容集合的全面性和及时性。为了确保不受干扰地继续我们的正常数据标引工作，CAS所有的科学家已经快速地转换为100%在家办工模式。这种工作方式对我们来说并不新鲜，因为我们部分内容团队的同事多年来一直采用的是在家办公模式。现有的基础设施确保了我们团队的无缝过渡、数据收集的及时性和高质量，我们的解决方案、服务和支持继续保持在COVID-19爆发之前的水平。

以独特的资源和洞察力

加速COVID-19研究

为了确保直接从事COVID-19研究的客户拥有最新的信息，CAS科学家全力以赴，加速将相关研究纳入CAS数据收录中，这些数据收录入库是我们的信息解决方案(包括SciFinderⁿ和STNext®)的基础。

我们的解决方案跨越了创新生命周期，能够加速COVID-19相关的研究和开发。利用SciFinderⁿ，研究人员能够挖掘相关病毒(如SARS和MERS)的丰富历史文献，确认对COVID-19有潜在活性的现有被批准的治疗方法，优化合成路线以增加面临短缺药物的产量。Formulus®减少了配方的迭代，将疗法和疫苗更快地推向市场，STN帮助知识产权专业人士探索各种潜在解决方案的全景。

来自SciFinder的COVID-19文献

我们的信息科学家团队也正在构建专门的开源数据集，以支持研究、数据挖掘、机器学习和分析应用程序。上周向公众提供的初始数据集包括来自CAS REGISTRY®(CAS登记号数据库)近5万个已知的抗病毒药物和相关化合物，以及相关元数据，包括CAS登记号、每个物质的物理特性和数据关联表。这是第一个贡献给Allen研究所用于人工智能的COVID-19公开研究数据集“CORD-19”的化学物质集。

如需了解更多关于CAS COVID-19抗病毒候选化合物数据集的信息，请点击下图。

美国化学文摘社科学家最近还在ACS Central Science期刊上发表了一份开放获取研究报告，总结了从COVID-19和SARS-CoV-2相关出版文献中获得的见解。主题包括临床表现和治疗选择，病毒结构和机制，抗病毒药物和诊断。由于SARS-CoV-2与其他冠状病毒相似，如SARS-CoV-1和MERS-CoV，因此以前对这些病毒的研究也适用于SARS-CoV-2。我强烈建议大家阅读并分享这些信息。

共同战“疫”

CAS专家随时为您服务

随着COVID-19带来的快速演变和复杂挑战，客户支持通常是最有效的。CAS科学家和技术人员的能力和专业知识可对您的COVID-19研究工作带来更多价值，他们可以为您提供免费咨询。我们的团队包括数百名科学家，他们通晓超过50种语言，在广泛的科学学科领域，以及信息管理、高级分析、预测合成等方面拥有专业知识。可能的合作机会包括使用我们的专业检索服务来快速获得所需的结果集或进行数据分析，定制某兴趣靶点相关的数据集，或与我们的科学家合作解决具有挑战性的制剂问题。

我们已准备好，在我们的能力范围内尽一切努力为大家在COVID-19方面的工作作出贡献。如果有其他方式CAS可以帮助您推进您的研究，欢迎您联系CAS客户中心([e-mail])或[e-mail]。

我们谨代表美国化学文摘社全体同仁，愿您和您的家人度过这前所未有的艰难时刻，平安、健康!

With more than 1.4 million confirmed COVID-19 cases (as of April 9, 2020), and many more likely going untested, researchers around the world are racing to find solutions to this daunting challenge. Approved drugs are being explored as treatments for those afflicted, vaccines to prevent the long-term spread are in development, as well as many other efforts beyond drug discovery. To keep frontline healthcare professionals safe, manufacturers are reimagining production processes to make critical supplies, such as hand sanitizer and mask filters, testing methods are being optimized to be faster and more accurate, materials for new germ-resistant masks are being developed and new systems to sterilize medical equipment are being designed. 

The scientists and technologists at CAS are all-in to conquer this challenge as well. As part of the global scientific community, we have an opportunity, and frankly an obligation, to do everything in our power to tackle this global pandemic that is significantly impacting so many lives. Aligned with our mission as a division of the American Chemical Society, we are leveraging all of our resources, expertise and capabilities to support this fight. As a specialist in scientific information solutions, we are providing resources and insight to accelerate COVID-19 research and analysis and are actively consulting with research and technology organizations around the globe to accelerate their efforts. Yet every day we ask ourselves, is there more we can do?

A new normal, but the same quality and commitment

The COVID-19 crisis is presenting unique challenges for everyone around the globe, including scientific researchers, patent offices and journal publishers. At CAS, our top priorities remain ensuring the success of our customers and the continuity of our operations, as well as the safety and well-being of our employees through this challenging time. 

CAS is committed to maintaining the comprehensiveness and timeliness of our content collection that all of our customers depend on despite these unique circumstances. To ensure we can continue our normal curation process uninterrupted, all of our scientists have successfully transitioned to a 100% work from home model. Working in this manner is not new to us, as some of our content team has been working off-site for years. This existing infrastructure ensured a seamless transition for our team, allowing the timeliness and quality of our data collection, as well as the availability of our solutions, services and support, to continue unchanged from pre-COVID-19 levels. 

Unique resources and insight accelerating COVID-19 research

To ensure our customers working directly on COVID-19 treatments have the most up-to-date information, CAS scientists have mobilized to expedite inclusion of relevant research into the CAS data collection that underlies our information solutions, including SciFinderⁿand STNext®. 
Our solutions, which span the innovation lifecycle, are uniquely able to accelerate COVID-19 related research and development. SciFinderⁿ allows researchers to mine the rich history of relevant literature on related viruses, such as SARS and MERS, identify existing approved therapies with potential activity against COVID-19, and optimize synthetic pathways to ramp up production of drugs facing shortages. Formulus® reduces formulations iterations to get therapies and vaccines to market faster, and STN helps IP professionals explore the landscape surrounding a wide range of potential solutions.    

COVID-19 Reference from SciFinder

Our team of information scientists is also building specialized open-source data collections to support research, data mining, machine learning and analytics applications. The initial data set made available to the public last week is comprised of nearly 50,000 known antiviral drugs and related chemical compounds assembled from CAS REGISTRY®, as well as related metadata including CAS Registry Number®, physical properties and connection tables for each substance. It was the first chemical substance collection contributed to the Allen Institute for AI’s COVID-19 Open Research Dataset “CORD-19”. 

CAS scientists also recently published an open access Research Report in ACS Central Science summarizing insights from relevant published literature related to COVID-19 and SARS-CoV-2. Topics included clinical manifestations and treatment options, viral structure and mechanisms, antiviral agents, and diagnostics. Because SARS-CoV-2 is similar to other coronaviruses, such as SARS-CoV-1 and MERS-CoV, therapies previously explored for these other viruses could also be applicable to SARS-CoV-2. I highly encourage everyone to read and share this information. 

In This Together  —— CAS expertise is at your disposal 

With a rapidly evolving and complex challenge like COVID-19, custom support is often most effective. To whatever extent the capabilities and expertise of CAS scientists and technologists are valuable to augment your COVID-19 research efforts, they are available to consult with you at no charge. Our team includes hundreds of scientists speaking over 50 languages with expertise in a wide range of scientific disciplines, as well as information management, advanced analytics, predictive synthesis, and much more. Possible opportunities include using our expert search service to get needed answers or analysis quickly, requesting custom-curated data sets relevant to a target of interest, or collaborating with our scientists on a challenging formulations problem. 

Truly, whatever we can do within our capacity to contribute to your efforts related to COVID-19, we are prepared to undertake. If there are additional ways CAS can help you advance your research, we welcome your outreach to the CAS Customer Center.

On behalf of all of us at CAS, we wish you and yours the very best as we all navigate this unprecedented and difficult time. Stay safe and be well!

Copyright © 2020 CAS, a division of American Chemical Society

长按下面二维码关注“ACS美国化学会"

点击“阅读原文” Click 'Read more'